Shares of Lilly and Novo Nordisk Are Trading Lower After Pfizer Selected Its Preferred Once-daily Modified Release Formulation for Danuglipron, a GLP-1 Receptor Agonist.
Shares of Lilly and Novo Nordisk Are Trading Lower After Pfizer Selected Its Preferred Once-daily Modified Release Formulation for Danuglipron, a GLP-1 Receptor Agonist.
輝瑞選擇其首選的每日一次改良釋放型達格列普汀GLP-1受體激動劑後，Lilly和Novo Nordisk的股票下跌。
Shares of Lilly and Novo Nordisk Are Trading Lower After Pfizer Selected Its Preferred Once-daily Modified Release Formulation for Danuglipron, a GLP-1 Receptor Agonist.
輝瑞選擇其首選的每日一次改良釋放型達格列普汀GLP-1受體激動劑後，Lilly和Novo Nordisk的股票下跌。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。